Novartis Cuts Growth Target and Shares Fall

Novartis lowered its annual sales growth target to 5% through 2031. The adjustment follows looming patent expiries and recent trial setbacks. Company shares dropped 3.3% after the announcement.

Xurve View
Insights:
FILE PHOTO: A view of the Novartis booth and logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake/File Photo

Novartis targets annual sales growth of 5% through 2031, falling short of prior expectations due to looming patent expiries. The new forecast trails the 5% to 6% annual growth range set last year for 2025 through 2030. Investors reacted by selling shares, pressuring the Swiss drugmaker ahead of a scheduled strategy update.